Company Description
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.
The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.
It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors.
In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease.
It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 10, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 150 |
| CEO | Paul J. Hastings |
Contact Details
Address: 1150 Veterans Boulevard South San Francisco, California 94080 United States | |
| Phone | (925) 407-1049 |
| Website | nkartatx.com |
Stock Details
| Ticker Symbol | NKTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001787400 |
| CUSIP Number | 65487U108 |
| ISIN Number | US65487U1088 |
| Employer ID | 47-4515206 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Paul J. Hastings | Chief Executive Officer, President and Director |
| Dr. Alicia J. Hager | Chief Legal Officer and Corporate Secretary |
| Alyssa Levin C.A., CPA | Chief Financial and Business Officer and Principal Accounting Officer |
| Dr. Ralph Brandenberger Ph.D. | Chief Technical Officer |
| Dr. James Trager Ph.D. | Chief Scientific Officer |
| Greg Mann | Vice President of Public Affairs and Investor Relations |
| Dr. David R. Shook M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | ARS | Filing |
| Apr 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 15, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 29, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 29, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 28, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 28, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 28, 2024 | 8-K | Current Report |